FDA fast-tracks prostate-cancer drug
7th Nov 2005, 18:12 GMT
The Food and Drug Administration has granted fast-track status to Dendreon Corp.'s Provenge to treat prostate cancer, the firm said Monday.
FDA fast-tracks prostate-cancer drug related news:
- FDA grants orphan drug status to AstraZeneca cancer drug — Pharmaceutical Business Review Online
- Tarceva gets FDA go-ahead for pancreatic cancer treatment — The Earth Times Online Newspaper
- Pancreatic Cancer Drug: FDA Approved — MedicineNet Cancer General
- Protein suppresses prostate cancer, enhances effects of vitamin E — KeralaNext: Science
- Research unveils new, reliable approach to drug delivery for cancer patients — EurekAlert! - Cancer
- Benefit of combining radiation and hormone therapy in the treatment of prostate cancer — News-Medical News Feed
- Tarceva granted FDA approval in pancreatic cancer — Pharmaceutical Business Review Online
- FDA approves Genentech drug in combo use — bizjournals.com Health Care:Pharmaceuticals headlines
- Researchers unveil reliable new approach to cancer drug delivery — Physics Org
- Prostate Cancer (PDQ®): Treatment — QualityTools
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Neurogen's obesity drug in phase 1 trial
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries